As of Q3'25, Eli Lilly's P/B Ratio stands at 33.555, reflecting a significant decline from its peak in Q4'23. The most recent data point indicates a continued downward adjustment in valuation compared to prior quarters. From Q1'23 to Q4'23, the P/B Ratio showed strong growth, rising from 33.113 to a high of 65.795. However, starting in Q1'24, the ratio began to decrease, with intermittent fluctuations, falling sharply to 33.555 by Q3'25. This trend suggests a period of elevated valuation followed by a sustained correction, indicating changing market sentiment or shifts in the company's book value relative to its market price over the observed period.